Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sunshine Act Hits Daylight Savings Time; PhRMA Seeks Extension For Physician Payment Reporting

Executive Summary

Industry groups have asked HHS Secretary Kathleen Sebelius to give companies additional time to collect and report their payments to physicians and teaching hospitals since HHS has yet to establish the procedures for doing so.

You may also be interested in...

GSK Champions More Trial Data Disclosure, But PhRMA Objects

In its latest move on the transparency front, Glaxo endorses the U.K.-driven AllTrials campaign, which calls for releasing all clinical trial results. Announcement runs counter to PhRMA’s defense against requirements for more disclosure.

Physician Sunshine Rule Needs Longer Lead Time Before Implementation, PhRMA Says; Scope Challenged By CROs

The Pharmaceutical Research and Manufacturers of America seeks at least a six-month lead time before implementation in comments to CMS. The Association for Clinical Research Organizations takes issue with including payments for “legitimate” research in the rulemaking at all.

HHS’ Holiday Gift To Industry: Delayed Collection Of Physician Payments Data

CMS postpones the deadline for drug makers to begin full implementation of the Sunshine Act until after it issues a final rule on how to collect the data. Current plans are to keep the March 31, 2013, deadline for companies to submit to HHS the data they do collect for 2012.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts